Smith & NephewSNN

The Federal Reserve raised interest rates this week, ending a long stretch of steady rates. For a medical technology company like Smith & Nephew, higher rates can be a double-edged sword. It makes the interest payments on its own debt more expensive and can also make it harder for hospitals to finance the purchase of expensive new surgical robots.

While the company is currently focused on an internal turnaround to improve its profit margins, a broader cycle of rising rates adds a layer of difficulty to that plan. We are watching whether this shift in the economy slows down hospital spending on the high-tech tools that Smith & Nephew relies on for its future growth.

Source: CNBC Television

Smith & Nephew has finalized its offer to buy back up to $250 million of its own debt. This involves purchasing notes that were originally set to be paid back in 2030. By buying these bonds back now, the company can reduce its future interest payments and manage its overall debt levels. This is a standard piece of financial housekeeping. While it shows the company has the cash to tidy up its balance sheet, it does not change the core challenge of improving its profit margins through its ongoing operational turnaround.

Jefferies analysts stood by their buy rating for Smith & Nephew, even as other investors expressed doubt about the company's ability to hit its growth targets. The firm pointed out that the stock is trading at a low valuation of about 12 times its expected earnings for 2027, which they believe makes it a bargain. While the company has struggled with inconsistent performance, this call suggests that the current low price already accounts for those risks. For a long-term owner, the focus remains on whether the company can successfully execute its plan to expand profit margins over the next few years.

Smith & Nephew announced that its Chief Financial Officer, John Rogers, will leave the company at the end of September. He is moving to a new position at Baxter, a medical technology firm in the U.S. While he stepped down from the board immediately, he will stay on for a brief transition period.

This departure is a setback because the company is currently in the middle of a major plan to improve its profit margins. Losing the person who oversees the finances during such a critical phase adds uncertainty. If you own the stock, the main thing to watch is how quickly and effectively the company finds a replacement to keep the turnaround on track.

Metrics we are tracking